Thursday, 18 June 2020

U.S. Personalized Medicine Market, Segments, Growth And Value Chain analysis 2019

The Personalized Medicine Market is the most recent trend in the multibillion–dollar molecular diagnostics industry. Pharmaceutical and biotechnology companies are increasingly turning to personalized medicine in order to improve the drug development process and also to speed up the approval or sanction of new drugs.
The U.S. Personalized Medicine market has been evaluated as average growing market and expected that the market will reach high growth figures in coming years. A factsheet published by the WHO states that about 17.5 million people die due to cancer and other diseases every year, which is about 31% of the deaths across the globe. These alarming statistics shows the obvious reason for growth of market with the U.S. Personalized Medicine market analysis. Major factors driving the U.S. Personalized Medicine market growth include growing occurrence of autoimmune diseases during the forecast period and various other disease.
U.S personalized medicine market is expected to grow at the CAGR of 7.5% during the forecasted period.
Various trends are responsible for influencing the growth trajectory of the US personalized medicine market. Personalized medicine promises enormous potential in the treatment of cancer. Personalized medicine has entered the mainstream in the treatment of oncology diseases and is changing the way such diseases are identified, treated and classified. According to the World Health Organization (WHO), cancer is one of the prime reasons for 31% of the deaths globally and each year about 17.5 Mn people die due to cancer. Surging prevalence of cancer across the US is a prime reason for the growth of the US personalized medicine market.
Strong research & development activities in the field of personalized medicine by industrial, academic, and government agencies continue to remain strong in the region which also supports the growth of the US personalized medicine market.
Increasing incidences of autoimmune diseases stimulate the growth of the US personalized medicine market. Also, the government in the US is extending its support in the form of funding for R&D activities; favorable NIH policies create a conducive environment for the growth of the US personalized medicine market.
Furthermore, a growing number of companies from outside the health industry are entering the personalized medicine space which is likely to provide an impetus to the growth of the US personalized medicine market. 
Industry Updates
  • In December 2018, researchers at the University of Utah developed a novel personalized medicine tool for inherited colorectal cancer syndrome. The results for the same was published in the journal Genetics in Medicine.
  • In December 2018, researchers at the Columbia University have made advancements in personalized medicine that can be helpful in the treatment of kidney diseases.
Segmentation
The US personalized medicine market has been segmented based on product, application, and end user. By product, the US personalized medicine market has been segmented into diagnostic, therapeutics, medical care and nutrition, and wellness and others. The diagnostic and therapeutic segment accounts for the largest share of the market.
By application, the US personalized medicine market has been segmented into diagnosis and intervention, drug development and usage, cancer genomics and others.
By end user, the US personalized medicine market has been segmented into hospitals, molecular diagnostic laboratories and testing centers, academic institutes, bio & health informatics companies, and others. End user-wise, the hospitals segment commands the largest share of the market owing to growing usage in hospitals. The molecular diagnostic laboratories and testing centers segment is the second largest segment.
Competitive Landscape
Personalized medicine is presenting new challenges as well as opportunities to the market players who are continually endeavoring make their mark in the market. Collaborations through mergers, acquisitions, partnerships, and others are key strategies utilized by the market participants to stay competitive and improve their product offerings. Sanofi, Pfizer Inc., Laboratory Corporation of America, Abbott, Becton Dickinson & Co., Quest Diagnostics, GE Healthcare,
CardioDx Inc., Asuragen Inc., Bristol-Myers Squibb, Siemens Healthcare Diagnostics Inc., are the notable players in the US personalized medicine market.
Posted by at No comments:

India CRO Market Segments, Opportunity, Growth And Forecast By End-Use Industry 2019

Market Synopsis of India CRO Market:
A Contract Research Organization (CRO) offers outsourced services to support R&D functions for pharmaceutical, biotechnology, and health companies. The services may be clinical research, product development such as drug development or process development such as bio analytical assay development. A CRO may also provide management services such as clinical trials management, and pharmacovigilance.
According to the analysis offered by Market Research Future (MRFR), the India CRO market has been presumed to flourish at a CAGR of 12.0% during the forecast period with overview of top cro companies in India.
The two important factors that are making India a favorable market for CRO include India’s acceptance of international guidelines and intellectual property rights. Other factors include the availability of the largest pool of patients and large hospitals, educated and accessible human resource (HR), low operational cost due to cheap HR, and lastly the presence of diverse types of climatic conditions that allow stability studies to be performed with ease in one destination. Some legal factors that favor the growth of India CRO market are efforts by the regulatory authorities such as Department of Biotechnology (DBT), Director Controller General of India (DCGI), Directorate General of Foreign Trade (DGFT), and Indian Council of Medical Research (ICMR).
The market constraints that can hamper the growth of India CRO market include growing concern for security especially data security and patient security and lack of collaboration between universities and industry etc. Sometimes, some unethical Indian CROs make dishonest comprises which creates trust issues among potential clients for CROs and hurts the market.
Segments:
India CRO market has been segmented on the basis of service types which comprises clinical trials, product development, process development, post-marketing surveillance, quality monitoring and others. On the basis of therapeutic application; market is segmented into oncology, cardiovascular, neurology, nephrology and urology, and others. On the basis of end users; market is segmented into pharmaceutical/biopharmaceutical companies, medical devices companies and academic institutes.
Regional Analysis of India CRO Market:
The western and southern regions of India hold a strong position in the CRO market due to their better infrastructure, education and salubrious climate. However the northern regions have started growing and catching up due to larger and more diverse genetic pool and the concentration of regulatory bodies in northern India. The faster growth of hospitals in northern India is favoring the CRO market and has led to this shift. The growth of diseases needing specialized care and treatments such as cancer is booming the CRO market of this segment at a faster pace than other segments.
India is emerging as a top destination for contract research organizations for the following reasons
  • India’s acceptance of International guidelines and intellectual property rights
  • Presence of diverse types of climatic conditions thus allowing stability studies to be performed with ease in one destination
  • Educated and accessible human resource in India
  • Presence of diverse ethnic pool thus enabling diverse sample for clinical trials
  • Low operational cost due to cheap human resource
  • Availability of largest pool of patients and large hospitals

Indian CRO Market - Competitive Landscape
The India CRO market is dominated by multinational CROs, followed by India CROs, multinational pharmaceutical companies, and Indian pharmaceutical companies. Among these, the Indian pharmaceutical companies are mainly engaged in conducting local trials.
In March 2018, The world's largest healthcare information provider and contract medical research, IQVIA, has recently stated that it is preparing to initiate outright buyouts to investments in start-ups for technologies that based on artificial intelligence and data analytics, while also considering those related to the healthcare sector as it converts into a "Human Data Science Company". Further, the company also stated that the investments in the future will be more directed towards development in the Asia Pacific region that includes China, India, Japan and South Korea where the company forecasts increasing demand for its services in the coming years.
In March 2018, Syngene International has entered into a multiyear R&D agreement with GlaxoSmithKline plc. The companies with this collaboration are focus to accelerate the discovery of new drug candidates using Syngene discovery services platforms.
Posted by at No comments:

Carcinoid Syndrome Management Market - Granular Market Report And Review, 2019

Market Scenario:
Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.
Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of global carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.
Segmentation:
The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented intochemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
Key players
  • Novartis International AG (Sandoz)
  • Pharmascience Inc.
  • Omega Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Ipsen Biopharmaceuticals, Inc.
  • Sirtex Medical Limited
  • BTG International Ltd.
  • Wockhardt Ltd.
  • Sun Pharmaceutical Industries Limited
Study Objectives:
  • To provide detail analysis of parent market and the changing market dynamics of the industry.
  • To provide detail analysis of the market structure along with estimated future growth forecast about various segments and sub-segments of the global carcinoid syndrome management market.
  • To provide in depth market segmentation and historical, current and projected market size in terms of value and volume with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future growth prospect.
  • To provide detailed analysis on recent industry trends and developments, strategies of key players and competitive landscape of the market.
  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place  in the global  Carcinoid Syndrome Management.
Regional Analysis
The Global Carcinoid Syndrome Management is segmented on the basis of regions, into North America, Europe, Asia-Pacific, and Middle East & Africa. America accounts for the largest market share of the Global Carcinoid Syndrome Management by region in 2016. High per capita healthcare expenditures followed by increasing awareness of the diseases and presence of the developed healthcare sector are the major drivers for the market growth during the forecast period. Followed by the North America, Europe holds the second largest market. Asia pacific is the fastest growing region. However, the Middle East and Africa region holds the least share of the global market, especially due to the presence of the poor economies within the Asia Pacific region. In the Middle East & African region, the Middle East holds the largest market share.
Posted by at No comments:

CBCT Dental Imaging Market 2019–By Identifying The Key Market Segments And Key Players Holding Market Share

Market Scenario:
Dental cone beam computed tomography (CT) is a special type of x-ray equipment used when regular dental or facial x-rays are not sufficient. The technology is used to produce three dimensional (3-D) images of the teeth, soft tissues, nerve pathways and bone in a single scan. The CBCT dental imaging industry is growing rapidly. The increasing use of 3D radiographic imaging in orthodontics and increasing adoption of CBCT imaging by dental professionals has boosted the revenue of this market. 
The U.S., India & Europe market is expected to reach USD 565.3 million by the end of the forecast period due to rising CBCT Dental Imaging Market Trends and is expected to grow at a CAGR of 9.8%.
Key Finding
  • The U.S., India & Europe CBCT dental imaging market and is expected to reach USD 565.3 million by 2023.
  • Regionally, U.S. holds the largest CBCT dental imaging market share of U.S., India & Europe CBCT dental imaging market and is expected to reach USD 280.9 million by 2023.
  • India market is expected to be the fastest growing market, and expected to grow at a CAGR of 10.3% from 2016 to 2023
Key Players for U.S., India & Europe CBCT dental imaging market:
Some of the key players in this market are: Carestream Health (US), Dentsply Sirona (US), FONA Dental, S.R.O., Gendex, Imaging Sciences International, LLC (US), J.MORITA MFG.CORP. (Japan), KaVo Dental GmbH (Germany), NewTom, Planmeca OY, Prexion (US), Sinclair Dental/Dentaire (Canada), SOREDEX (Finland), Vatech Networks (Republic of Korea) and others.
Segments:
U.S., India & Europe CBCT dental imaging market has been segmented on the basis of type of detector which comprises of flat panel detectors, image intensifier. On the basis of application the market is segmented into dental implants, endodontics, orthodontics and others. On the basis of end users the market is segmented into hospitals & dental clinics, academic & research institutes and others.
Regional Analysis of U.S., India & Europe CBCT dental imaging market:
U.S. is the largest market for CBCT Dental Imaging market. The U.S. market for CBCT dental imaging is expected to grow at a CAGR of 9.5% and is expected to reach at USD 280.9 Million by the end of the forecast period.
Europe is the second-largest market for CBCT dental imaging which is expected to grow at a CAGR of 10.0%. India region is expected to be fastest growing region in CBCT dental imaging market.
The report for U.S., India & Europe CBCT Dental Imaging Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regionsTop of Form
Posted by at No comments:

Market Therapeutics In Global Markets To 2023 - Growth Driven By Increasing Uptake Of Targeted Therapies And Rising Prevalence

Market Scenario:
Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis.

The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.
The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.
The market restraints are loss of patents of block busters, greater penetration of generics and fragmentation of market, poor efficacy and side effects of present therapies, non-life threatening nature and poor symptoms of osteoporosis etc.
Taking all the factors into consideration, we expect the global osteoporosis market which totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a CAGR of 4.7%.
Study Objectives Global Osteoporosis Drugs Market:
  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global osteoporosis drugs market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by drug class (bisphosphonates, calcitonins, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others), by route of administration (oral, injectable and others) and by gender (male, female and children).
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Key Players for Global Osteoporosis Drugs Market:
Some of the key players in this market are: Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others.

Segments:
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.

Intended Audience:
  • Osteoporosis Drugs Manufacturers
  • Osteoporosis Drugs Suppliers
  • Private Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Government Research Laboratories
  • Contract Manufacturing Organizations
Regional Analysis of Global Osteoporosis Drugs Market:
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.
The report for Global Osteoporosis Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Posted by at No comments:

Wednesday, 17 June 2020

Soft Tissue Repair Market 2020 Growing Trend And Demand In Healthcare Sector 2023

Market Insights:
The Global Soft Tissue Repair Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 5200 million in 2017 and is projected to register a CAGR of 6.2% over the forecast period.
Various other factors such as increasing awareness about orthopedic disorders and other related conditions, improvement in reimbursement policies, untapped emerging markets, and increasing healthcare expenditure are also expected to propel the growth of the market.
The xenograft implant is designed for the surgical repair of damaged or ruptured membranes. The rising cases of sports-related injuries and technological advancements are some of the key factors driving the soft tissue repair market size. For instance, in 2016, Colorado Therapeutics received FDA approval for its xenograft implant.
However, the high cost of advanced equipment and a shortage of physicians in emerging markets can hamper market growth over the forecast period.
Key Players
Some of the key players in the global soft tissue repair market are Stryker Corporation, C.R. Bard, Inc., Arthrex, Inc., Integra LifeScience Corporation, Depuy Synthes, Smith & Nephew plc, Allergan Plc., Athersys, Inc., CryoLife, Inc., Medtronic Plc., Organogenesis Inc., Zimmer Biomet Holdings, Inc., Lifenet Health, Inc., American Medical Systems Inc., U.S. Stem Cell, Inc., Wright Medical Group, Inc., Isto Biologics, and others.
Segmentation
The global soft tissue repair market is segmented based on product, application, end user, and region.
the global market for soft tissue repair, by product, is segmented into fixation products, tissue patch/match, laparoscopic instrument, and others. The fixation products segment is further classified as a suture, suture anchors, and interference screw. The tissue patch/match segment is further classified as biological, and synthetic. The biological segment includes allograft and xenograft.
Based on application, the market is segmented into orthopedic surgery, skin repair, hernia repair, vaginal sling repair, dental reconstruction, cardiovascular surgery, breast reconstruction, and others.
Based on end user, the market is segmented into hospitals, clinics, research & academic institutes, and others.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The soft tissue repair market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European soft tissue repair market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The soft tissue repair market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The soft tissue repair market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for soft tissue repair owing to the increasing healthcare expenditure presence of major market players and rising geriatric population within the region. As per the data suggested by the United Census Bureau, by 2060, the US is projected to grow by 79 million people, from about 326 million today to 404 million. The population is projected to cross the 400-million threshold in 2058.
In 2017, it was estimated that Europe stood second in the global soft tissue repair market. Robust research and development (R&D) sector along with the availability of funding opportunities in research and innovation will support the market growth.
Asia-Pacific (APAC) is expected to represent the phenomenal market growth throughout the forecast period due to increasing demand for medical technology, growing health awareness, and growing aging population coupled with the rising prevalence of orthopedic diseases in India, Japan, and Australia. For instance, according to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, around 12.4% of the population in the region was 60 years or older and is projected to reach to more than 1.3 billion by 2050.
On the other hand, the Middle East and Africa held the least share in the global soft tissue repair market due to the low economic development, especially within the African region.
Posted by at No comments:

Pharmaceutical Analytical Testing Outsourcing Market 2020 Global Overview, Regional Analysis, Size, Share And Forecast To 2023

Global Pharmaceutical Analytical Testing Outsourcing Market Analysis: by Product Type (Raw Materials, API, Others), by Service (Bioanalytical Testing, Stability Testing, Others), by End User (Pharma Companies, Others), & by Region—Forecast till 2023
Market scenario
Increasing research and development investments is the key factor driving the pharmaceutical analytical testing outsourcing market. For instance, in 2018, Almac Group announced that it will invest USD 493,000 in additional nuclear magnetic resonance instrumentation at its headquarters in Craigavon, UK.
The Global Pharmaceutical Analytical Testing Outsourcing Market is slated to expand at a considerable rate and at a healthy 7.45% CAGR over the predicted years (2018-2023). Analytical testing plays a key role in the field of pharmaceutical development right from the initial stages of commercialization of the therapy or drug. It is a vital phase in drug manufacturing that includes identification, determination as well as purification of a single compound and/or mixture of compounds. This process also includes determining the chemical compounds’ structure along with helping in the characterization and synthesis of active pharmaceutical ingredients (APIs).
Various other factors such as intense competition among pharmaceutical companies, increasing awareness about product quality, and safety and changing regulations for in vivo and in vitro tests are also expected to propel the growth of the market.
However, lack of awareness, and quality approvals and regulatory audits conducted in outsourcing laboratories can hinder the market growth over the forecast period.
Key players
Some of the key players in the global Pharmaceutical Analytical Testing Outsourcing market are SGS SA, Toxikon, Inc, Eurofins Scientific, Pace Analytical Services LLC, Intertek Group plc, Pharmaceutical Product Development, LLC, Exova Group plc, Boston Analytical, Charles River Laboratories International, Inc, West Pharmaceutical Services, Merck KGaA, WuXi AppTec, Source BioScience and others.
Segmentation
The Global market for pharmaceutical analytical testing outsourcing, by product type is segmented into raw materials, finished products and active pharmaceutical ingredients.
The market, by services, is segmented into bioanalytical testing, method development & validation, stability testing, and others. The bioanalytical testing segment is further classified as clinical and non-clinical. The method development & validation segment is further classified as extractable & leachable, impurity method, technical consulting and others. The stability testing is further classified as drug substance, stability indicating method validation, accelerated stability testing, photostability testing and others.
Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations and others.
Regional Market Summary
The Americas dominated the global market for pharmaceutical analytical testing outsourcing. This can be attributed to the presence of major market players and increasing awareness about product quality, and safety within the region.
Europe stood second in 2017 owing to the increasing participation of market players and presence of developed economies like UK, Germany, France, and others within the region provides a driving force for the market to grow. In 2017, Eurofins Scientific acquired EAG Laboratories to enter into the dynamic and growing Materials and Engineering Sciences markets.
Asia Pacific was projected to be the fastest growing region in 2017. Factors such as growing research and development investment, increasing penetration of the market players within the region, and increasing government’s support for foreign investments drives the regional markets of the Asia Pacific region.
On the other hand, the Middle East and Africa held least share in the global pharmaceutical analytical testing outsourcing market due to the presence of poor economies and low per capita income, especially within the African region. The Middle Eastern region is estimated to be a major market for the Middle East and African region.
Posted by at No comments:
Subscribe to: Posts (Atom)